FIELD: medicine.
SUBSTANCE: invention relates to specific compounds given in the patent claim. Compounds of the invention are intended for inhibiting the activity of cathepsin K.
EFFECT: compounds are intended for preparing a drug suitable for treating osteoporosis, osteoporosis caused by glucocorticoids, Paget's disease, abnormally increased bone tissue metabolism, periodontal disease, loss of teeth, fractures of bones, rheumatoid arthritis, osteoarthritis, periprosthetic osteolysis, imperfect osteogenesis, atherosclerosis, obesity, glaucoma, chronic obstructive pulmonary disease, metastatic bone disease, malignant hypercalcemia or multiple myeloma.
6 cl, 1 tbl, 159 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CATHEPSIN-CYSTEINE PROTEASE INHIBITORS | 2003 |
|
RU2312861C2 |
| CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | 2014 |
|
RU2655380C2 |
| NOVEL CYCLOPENTANE DERIVATIVES | 2010 |
|
RU2572555C2 |
| 1-CYANOCYCLOPROPYL DERIVATIVES AS CATHEPSIN K INHIBITORS | 2008 |
|
RU2470023C2 |
| CYSTEIC CATHEPSIN PROTEASE INHIBITOR | 2005 |
|
RU2399613C2 |
| INDANYL COMPOUNDS | 2009 |
|
RU2474572C1 |
| 1-(4-ISOXAZOLE-5-YL)-1H-PYRAZOLE-1-YL)-2-METHYLPROPANE-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-17 AND IFN-GAMMA INHIBITORS FOR TREATMENT OF AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION | 2018 |
|
RU2785342C2 |
| SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS | 2002 |
|
RU2303032C2 |
| AZABICYCLO{3,1,0}HEXANE DERIVATIVES USED AS DOPAMINE RECEPTOR D3 MODULATORS | 2005 |
|
RU2434011C2 |
| PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | 2010 |
|
RU2535479C2 |
